Breaking News

Sangamo Therapeutics, Prevail Ink Novel Engineered Capsids Agreement

Prevail will evaluate Sangamo’s capsids with an option to obtain an exclusive license to use the capsids for certain neurological targets.

Sangamo Therapeutics, Inc., a genomic medicine company, signed an evaluation and option agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Co., granting Prevail rights to evaluate certain adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets. Generated through Sangamo’s AAV capsid engineering platform, SIFTER (Selecting In vivo For Transduction and Expressio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters